BiotechTube

Isavuconazole

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematologic Malignancy

Conditions

Hematologic Malignancy, Myeloproliferative Disorder

Trial Timeline

May 4, 2017 → Nov 8, 2021

NCT ID
NCT03149055

About Isavuconazole

Isavuconazole is a phase 2 stage product being developed by Astellas Pharma for Hematologic Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT03149055. Target conditions include Hematologic Malignancy, Myeloproliferative Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT03149055Phase 2Completed
NCT01657890Phase 1Completed
NCT01555866Phase 1Completed
NCT00634049Phase 3Completed

Competing Products

20 competing products in Hematologic Malignancy

See all competitors
ProductCompanyStageHype Score
120 mg LY2784544Eli LillyPhase 2
52
RLYB116 for InjectionRallybioPhase 1
25
DS3790a + Combination drug + Combination drugDaiichi SankyoPhase 1/2
41
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
DSP-5336 + [14C]-DSP-5336Sumitomo PharmaPhase 1
33
BBI608 + Dexamethasone + Bortezomib + Imatinib + IbrutinibSumitomo PharmaPhase 1
33
Venetoclax + ethinyl estradiol/levonorgestrelAbbViePhase 1
33
ABT-888 + TemozolomideAbbViePhase 1
33
ABBV-101AbbViePhase 1
33
elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injectionAbbViePhase 2
52
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
AZD9829 + AZD9829AstraZenecaPhase 1/2
41
ridaforolimusMerckPhase 2
52
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
Ondansetron + AprepitantMerckPhase 2
52
NemtabrutinibMerckPhase 2
52
ARQ 621MerckPhase 1
33
NemtabrutinibMerckPhase 1
33
PelabresibNovartisPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85